2008
The Role of ICOS in Peripheral Inflammation in Lupus
Eardley L, Odegard J, Craft J. The Role of ICOS in Peripheral Inflammation in Lupus. The FASEB Journal 2008, 22: 668.18-668.18. DOI: 10.1096/fasebj.22.1_supplement.668.18.Peer-Reviewed Original ResearchCostimulatory molecule ICOST cellsPeripheral inflammationDendritic cellsChemokine receptorsMRL/Faslpr miceExpression of CCR6Role of ICOSChemokine receptor expressionMajority of CD4Role of CD4Lupus-prone miceSevere renal diseaseFaslpr miceIndependent cytokinesLupus nephritisEffector cytokinesIL-10Lupus miceRenal diseaseCellular infiltrateChemokine productionSuch inflammationIL-5Certain chemokines
2007
CNS lupus in MRL/Faslpr mice (130.15)
Choi J, Chahboune H, Hyder F, Craft J. CNS lupus in MRL/Faslpr mice (130.15). The Journal Of Immunology 2007, 178: s230-s230. DOI: 10.4049/jimmunol.178.supp.130.15.Peer-Reviewed Original ResearchMRL/Faslpr miceFaslpr miceDiffusion tensor imagingControl miceStructural abnormalitiesCentral nervous system injurySpontaneous autoimmune diseaseLupus-prone miceNervous system injuryToll-like receptorsWeeks of ageCNS lupusIg depositionNeurological deficitsHuman SLENeuropsychiatric involvementSystem injuryAntibody depositionAutoimmune diseasesDTI alterationsMRL miceChoroid plexusMiceTensor imagingHippocampus
2006
Abrogation of skin disease in LUPUS‐prone MRL/FASlpr mice by means of a novel tylophorine analog
Choi J, Gao W, Odegard J, Shiah H, Kashgarian M, McNiff JM, Baker DC, Cheng Y, Craft J. Abrogation of skin disease in LUPUS‐prone MRL/FASlpr mice by means of a novel tylophorine analog. Arthritis & Rheumatism 2006, 54: 3277-3283. PMID: 17009262, DOI: 10.1002/art.22119.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusEnd-organ diseaseInflammatory skin diseaseMRL/Skin diseasesMRL/Faslpr miceFemale MRL/NF-kappaB inhibitorFlow cytometric analysisFaslpr miceAutoantibody titersIgG levelsLupus erythematosusLymph nodesRenal diseaseVehicle treatmentKidney diseaseHepatic toxicityTotal IgMTylophorine analogsAntichromatin autoantibodiesTherapeutic effectHistopathologic analysisMurine modelSignificant abrogation